CN1430518A - 干酪乳杆菌在免疫刺激肽中的应用 - Google Patents
干酪乳杆菌在免疫刺激肽中的应用 Download PDFInfo
- Publication number
- CN1430518A CN1430518A CN01810051A CN01810051A CN1430518A CN 1430518 A CN1430518 A CN 1430518A CN 01810051 A CN01810051 A CN 01810051A CN 01810051 A CN01810051 A CN 01810051A CN 1430518 A CN1430518 A CN 1430518A
- Authority
- CN
- China
- Prior art keywords
- group
- actimel
- application
- placebo
- lactobacillus casei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000199866 Lactobacillus casei Species 0.000 title claims description 19
- 235000013958 Lactobacillus casei Nutrition 0.000 title claims description 16
- 229940017800 lactobacillus casei Drugs 0.000 title claims description 16
- 230000003308 immunostimulating effect Effects 0.000 title description 3
- 102000004196 processed proteins & peptides Human genes 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 244000000010 microbial pathogen Species 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 235000021001 fermented dairy product Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 10
- 229940039696 lactobacillus Drugs 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 35
- 102000036639 antigens Human genes 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 35
- 229940068196 placebo Drugs 0.000 description 33
- 239000000902 placebo Substances 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- 238000011160 research Methods 0.000 description 19
- 206010022000 influenza Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 206010043376 Tetanus Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 206010007134 Candida infections Diseases 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 201000003984 candidiasis Diseases 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 4
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241001478240 Coccus Species 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013179 statistical model Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 244000000022 airborne pathogen Species 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000007983 food acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000012887 quadratic function Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001814 trypan blue Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/245—Lactobacillus casei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及干酪乳杆菌在口服给药来加强特异性针对病原微生物的免疫的组合物中的应用。所述组合物可以特别是食品或食品添加物。
Description
本发明涉及乳酸菌加强抗传染性物质的特异免疫反应的用途。
乳酸菌(LABs)通常用于生产发酵食品,尤其是乳制品。
Metchnikoff的研究(The prolongation of life.第1版,NewYork:GP Putman’s Sons,1908)最初提示了乳酸菌对健康的作用,并从此成为许多研究的主题。
现在通常承认各种乳酸菌可发挥有益于健康的作用。这些细菌也称作“益生菌”-表示当它们被足量摄取时,除了常规的营养作用外,还对健康发挥积极作用的活微生物的名称。在属于乳杆菌属、双歧杆菌属、链球菌属和乳球菌属的种中已特别描述了益生菌,一般用于乳品工业。
认为益生菌通过妨碍病原微生物的发展,和/或更直接作用于免疫系统来特别干预肠道菌群的水平。例如,已经观察到益生菌或含这些细菌的发酵食品如酸乳酪的摄入导致病原细菌减少;在免疫系统方面,已经报道了各种作用:活化参与特异性或非特异性免疫反应的细胞,如淋巴细胞和巨噬细胞,免疫球蛋白,尤其是IgA水平增加;免疫系统活化细胞因子水平增加等。(综述,参见例如MEYDANI和HA(Am JClin Nutr,71,861-7217,2000)。
总之,对各种益生乳酸菌进行的研究趋向总结出有些种,或至少这些种的有些株具有免疫刺激性能。另一方面,这些性能所基于的机制,和潜在参与的免疫系统成分仍未确定。因此看来有必要阐明这些方面,尤其是为了提出益生菌各种种或株的更好的目标应用。
在人和动物中实施的几个研究提示,干酪乳杆菌(Lactobacilluscasei)种的细菌对健康具有有益作用,特别是对免疫系统有积极作用。
已经表明在小鼠中,摄入含干酪乳杆菌株DN-114 001的发酵牛奶可增加抵抗鼠伤寒杆菌的感染[PAUBERT-BRAQUET等.Int JImmunother,4:153,(1995)];同时观察到巨噬细胞活化和循环IgAs增加。
菌株DN-114 001已于1994年12月30日保藏在巴黎,25 rue duDocteur Roux,Institut Pasteur的CNCM(Collection Nationale deCultures de Microorganismes)[国立微生物保藏中心],保藏号为I-1518;在PCT申请WO 96/20607(申请人为COMPAGNIE GERVAISDANONE)中描述了这个株,和其酸乳酪发酵组合用于制备发酵乳制品。
在人中进行的最近研究也报道了含干酪乳杆菌株DN-114 001的发酵牛奶的摄入促使加强抵抗鼠伤寒杆菌。这个作用归功于对非特异性先天免疫的作用[YOON等,Iht J Immunother;15,79-89(1999)]。
发明人研究了干酪乳杆菌是否也对适应性免疫有作用,它与先天免疫不同,引起对抗给定病原物的特异性免疫反应。
为了这个目的,发明人研究了体内口服给予干酪乳杆菌对响应各种普通病原物的代表性抗原:细菌抗原(破伤风);真菌抗原(念珠菌)和病毒抗原(流感)的T细胞增殖离体刺激的作用。
他们观察到对于每个测试的抗原,干酪乳杆菌摄入导致T细胞,特别是CD3+亚群响应所述抗原活化的增殖能力增加。这个作用尤其表现在流感抗原的情况下。
本发明的主题是干酪乳杆菌物种的菌株在制备可口服给药来加强抗病原微生物的特异性全身免疫反应的组合物中的应用。
这种免疫反应的加强是由对所述病原微生物抗原特异性的T细胞增殖能力增加而产生的。
根据本发明的优选实施方案,所述微生物是空气传播病原体,特别是呼吸道病原体。
有关的病原体特别是细菌或病毒;在后者中,将提到,例如,鼻病毒、呼吸道合胞病毒(RSV)和粘液病毒(正粘病毒如流感病毒)(甲、乙、或丙型流感),或副粘病毒,尤其是副流感病毒)。
本发明的实施方案中,所述干酪乳杆菌可单独或与干酪乳杆菌物种或其它物种的其它乳酸菌联合使用。有利地,它可与酸乳酪酵素,即保加利亚乳杆菌(Lactobacillus bulgaricus)和唾液链球菌嗜热亚种(Streptococcus thermophilus)组合使用。
它也可以以完整细菌的形式使用,可以是或可以不是活的,也可以以细菌溶菌产物的形式,或以细菌级分的形式使用。
优选,在根据本发明的应用中制备的组合物中每毫升含有至少105,优选至少106,通常在1×108和1.5×109之间的干酪乳杆菌细胞。
当干酪乳杆菌与酸乳酪酵素组合使用时,所述组合物中每毫升也有利地含至少107,优选2×108和1×109之间的唾液链球菌嗜热亚种细胞,和每毫升至少5×105,优选4×106和2×107之间的保加利亚乳杆菌细胞。
尤其最适合用于本发明的干酪乳杆菌株是CNCM株I-1518。
根据本发明制备的组合物可以以食品或食品添加物的形式给予。它们可以是例如,乳制品,特别是发酵乳制品,它们至少含所述干酪乳杆菌株,任选与其它乳酸菌组合,例如与酸乳酪酵素组合。
根据本发明制备的组合物可用于传染起源,特别是病毒起源,尤其是流感起源的病理情况的预防和治疗。优选,为了获得最佳的效果,它们将以相当于吸收至少107,优选至少108,通常在109和1012之间的干酪乳杆菌细胞的量给药至少一周,优选至少10天。
在随后的进一步描述的帮助下,将更清楚地理解本发明,该描述是指阐明干酪乳杆菌株加强对微生物抗原的特异性反应的性质的非限制性实施例。
实施例1:干酪乳杆菌对响应抗原刺激的T细胞增殖的作用
为了检测摄入含干酪乳杆菌菌株DN-114 001(CNCM I-1518)的发酵乳制品对响应抗原刺激的T细胞增殖的作用,实施与安慰剂相比的双盲实验。
该研究的条件如下:
个体
募集华盛顿医院中心传染病科(华盛顿特区)的88个健康个体,18至50岁。有肝炎或肾病,心血管功能紊乱,免疫或胃肠道疾病,严重哮喘或糖尿病病史的个体,在开始研究前少于3个月,用抗生素或免疫抑制剂治疗的个体,有酗酒或酒精依赖性病史的个体,已知对乳制品不耐受或过敏的个体,低卡路里饮食的个体,前季期间已接种抗流感疫苗的个体,和孕妇或哺乳妇女从本研究中排除。
WHC研究委员会批准了本研究的方案和条件,管理对人实施研究的机构审查部也批准。
所选个体随机分成2组:
-47个个体的一组(26个女性和21个男性)接受每天100ml含2%脂肪的发酵乳制品,包括酸乳酪酵素(保加利亚乳杆菌和唾液链球菌嗜热亚种)和干酪乳杆菌菌株DN-114 001,由DANONE以ACTIMEL商标销售。
-41个个体的一组(22个女性和19个男性)接受28天安慰剂:每天100ml用水稀释(1/5,v/v)的补充糖以给予与ACTIMEL等同卡路里值的牛奶。
要求2个组的个体在研究期间避免食用酸乳酪或其它发酵乳制品。
ACTIMEL组和安慰剂组的个体平均(圆括号中指出标准差)年龄分别是36(7.3)和32.7(7.4)。
为了确定基础值,在ACTIMEL或安慰剂开始摄入前,从2个组的每个个体抽取血液样品(55ml)。在9、18和28天给予个体控制随访,完成有关他们健康、可能的副作用以及任何可能干扰结果解释的疾病发展的短调查表。为了免疫学实验,每次随访期间抽取血液样品。
对于每个个体的血液样品,进行完整血细胞计数和血液化学分析。此外,用流式细胞术进行白细胞及其亚群(T细胞和亚群,B细胞,单核细胞和NK细胞)的表型分析。
细胞增殖的测定
通过如下所述测定3HTdR掺入来离体确定ACTIMEL组个体和安慰剂组个体,有关三个微生物抗原:念珠菌、破伤风和流感的T细胞增殖反应。
细胞制备:
所取的每个样品的30ml肝素化血液处理如下:将管以1500rpm离心10分钟。小心地将血浆转移到标记的冷冻管中并在70℃保存[原文如此]。血液转移到15ml离心管中并用PBS稀释到1∶3。将10mlFicoll-hypaque加入到50ml离心管中并覆盖30ml稀释的血液。管以2000rpm在室温下离心2分钟。弃去PBS上层,混合单个核细胞并转移到15ml离心管中。加入10ml HBSS,涡旋并以1500rpm离心10分钟;弃去上清,沉淀重悬于2-3ml HBSS。加入8ml HBSS,将管以1500rpm离心6分钟。这个方案重复两次,回收的细胞重悬于1-2mlPBS然后涡旋。计数细胞,台盼蓝排除法检查它们的活力,其浓度调整到2×108/ml。
制备抗原:
破伤风抗原:实验当天制备。PBS中将破伤风类毒素(CONNAUGHTLABORATORY,Willowdale,加拿大)稀释到1∶1000制备原液。
白色念珠菌(Candida albicans)抗原:PBS中将白色念珠菌抗原(BAYER CO,ELKERT,IN)稀释到1∶1000制备原液。
流感抗原:PBS中将流感病毒抗原(NIBSC,Herts,英国)稀释到1∶125制备原液。
使用微滴定板(96孔)。每个孔接受100μl抗原原液和100μl细胞,每孔2×105个细胞的终浓度。对照孔接受100μl PBS代替抗原原液。板在37℃,5%CO2下温育5天;温育结束前18小时,加入20μl的50μCi/ml3HTdR(NEW ENGLAND NUCLEAR,Boston,MA)。在滤器上收获每个板的孔的细胞,为了测定3HTdR掺入,滤器直接在MATRIX 9600 beta-计数器(PACKARD INSTRUMENTS)中计数,以CPM(每分钟计数)表示。
对于已接受ACTIMEL的组的每个个体和已接受安慰剂的组的每个个体,根据下列公式测定刺激指数(SI)估计增殖:
统计学分析
描述性统计学(平均数、标准差、中值)用于总结在每个测定时间,本研究的每个组中T细胞接触每个抗原的增殖反应。由于增殖反应的分布偏差,对增殖数据进行自然对数转换。
与基础值比较增殖反应的变异用于统计学建模[LITTELL等.SASSystem for Mixed Model.North Carolina:SAS Institute Inc,(1996)]。使用DIGGLE等[Analysis of Longitudinal Data.NewYork:University Press Inc,1994]描述的曲线平滑技术表现增殖反应与基础值相比较随时间的变化。
开发了混合线性模型以研究增殖反应的轨迹(trajectory)。这个模型允许将研究的每组的增殖数据调整为二次曲线。
这个模型由下列等式定义:Yijt=αij+β1jT+β2jT2+εijt,i=1,….n,j=1,2,t=1,2,3,4
其中:
Yijt表示个体i在产品组j在时间t时,与基础值相比的增殖反应的差异;对每个变量已经进行自然对数转换,Yijt=Log(在时间t的增殖)-Log(基础值)。
αij表示在产品组j中个体i的截距(interception)。它反应在模型中的随机作用。αij~MVN(O,G),G含有对角线结构(djagonalstructure)中方差的分量(MVN:多项式变量分布(multinomalvariable distribution))。
β1j和β2j是产品组j的T和T2的回归系数;
T是测定的时刻(第0,9,18或28天),T2是T的二次方。
εijt是误差系数:
εijt~MVN(O,R)和R=σ2In,其中In表示单位矩阵n×n。
实施了下列假说的统计学检验:
a)检测估计的回归系数是否是0.H0:β1j=0对H1:β1j≠0 (对于线性项)和H0:β2j=0对H1:β2j≠0 (对于二次项)如果β1j和β2j不同于0,则没有轨迹。如果β2j与0有显著差异,则有二次轨迹。如果只有β1j与0有显著差异,则有线性轨迹。
b) 比较两组的轨迹是否相同。H0:β11=E12对H1:β11≠β12 (对于线性项)和H0:β21=E22对H1:β21≠β22(对于二次项)用SAS统计包进行分析。结果下表I给出了有关个体的人数统计数据和增殖的基础值的估计。
表I
SD=标准差
人数统计数据和基础值 | 安慰剂 | ACTIMEL | 安慰剂与ACTIMEL比较 |
性别 女性男性 | 2219 | 2621 | 卡方检验p=0.826 |
年龄 平均数(SD)中值 | 32.7(7.4)31 | 36.0±7.337 | T检验P=0.038 |
人种 白色黑色其他 | 26123 | 25175 | 卡方检验精确p=0.652 |
白细胞 平均数(SD)中值 | 5997(1451)5992 | 5810(1399)5990 | T检验P=0.540 |
淋巴细胞 平均数(SD)中值 | 1932(567)1812 | 2009(554)1993 | T检验P=0.519 |
CD3+CD4+ 平均数(SD)中值 | 865(327)740 | 907(325)818 | T检验P=0.546 |
CD3+CD8+ 平均数(SD)中值 | 469(205)417 | 431(181)403 | T检验P=0.360 |
CD3+CD25+ 平均数(SD)中值 | 380(200)349 | 408(182)392 | T检验P=0.489 |
CD3+CD45+ 平均数(SD)中值 | 1384(488)1354 | 1411(434)1382 | T检验P=0.783 |
T细胞对特异性微生物抗原的增殖反应
下表2给出了每组(ACTINEL和安慰剂)在各个采样时间的外周血液单个核细胞(PBMCs)的离体增殖的平均数、标准差和中值。
表2
SD=标准差
抗原 | 安慰剂 | ACTIMEL | ||||||
0天 | 9天 | 18天 | 28天 | 0天 | 9天 | 18天 | 28天 | |
念珠菌平均数SD中值 | 2.32.01.5 | 2.73.11.7 | 2.94.11.6 | 1.91.21.6 | 3.03.41.7 | 3.23.51.7 | 4.35.62.0 | 2.32.61.4 |
破伤风平均数SD中值 | 7.37.85.2 | 11.812.36.3 | 7.98.05.1 | 8.78.16.7 | 8.415.83.5 | 8.710.45.2 | 10.311.85.0 | 7.88.25.1 |
流感平均数SD中值 | 14.211.411.1 | 21.719.116.5 | 17.019.69.8 | 17.315.712.0 | 13.012.69.6 | 19.717.116.9 | 20.316.617.0 | 13.912.711.0 |
本研究对于三个微生物抗原的增殖反应的基础值(0天),两组之间没有显著性差异。
图1图解了本研究的两组对于每个抗原在时间上的增殖反应的变化:ACTIMEL组:连续线;安慰剂组:虚线。
下表3提供了统计学建模结果。
表3
念珠菌:
抗原 | 变量 | 参数估计 | 标准误 | H0检验:参数=0 | 2条曲线的比较 |
念珠菌 | 安慰剂 TT2 | 0.017-0.0007 | 0.0140.0005 | P=0.232P=0.208 | H0:β11=β12P=0.540H0:β21=β22P=0.458 |
ACTIMEL TT2 | 0.028-0.0012 | 0.0130.0005 | P=0.030P=0.013 | ||
破伤风 | 安慰剂 TT2 | 0.034-0.0008 | 0.0140.0005 | P=0.022P=0.141 | H0:β11=β12P=0.630H0:β21=β22P=0.626 |
ACTIMEL TT2 | 0.043-0.0011 | 0.0130.0005 | P=0.001P=0.020 | ||
流感 | 安慰剂 TT2 | 0.022-0.0004 | 0.0170.0006 | P=0.181P=0.475 | H0:β11=β12P=0.045H0:β21=β22P=0.027 |
ACTIMEL TT2 | 0.068-0.0023 | 0.0150.0006 | P=0.0001P=0.0001 |
在ACTIMEL组中,0天的基础反应3.0±3.4增加到第9天的3.2±3.5,和第18天的4.3±5.6,然后在28天降到2.3±2.6(表2)。估计的线性项T和二次项T2的系数分别是0.028和0.0012(表3)。两个值与0有统计学显著差异(分别是p=0.030和0.013)。这些观察结果暗示对念珠菌抗原的增殖反应的变化具有显著的正趋向。增殖反应首先增加然后降低,如图1a所示。
安慰剂组显示本研究期间的小改变。估计的T和T2的回归系数是0.017和0.0007。这些值与0没有显著差异(分别是p=0.232和0.208)。这些观察结果显示对照组增殖反应在本研究期间没有显著改变。如图1a所示,安慰剂组曲线比ACTIMEL组的曲线平坦。尽管ACTIMEL组与安慰剂组相比,显示出明显的轨迹,两条曲线间的差异没有达到统计学显著性的水平(T的p=0.540和T2的p=0.458,表3)。
破伤风:
对于ACTIMEL组,反应从基础水平逐渐增加到第18天,然后下降。估计的T和T2的回归系数分别是0.043和0.0011(表3)。这两个值与0有显著差异(分别是p=0.001和0.020)。如念珠菌的情况,ACTIMEL组在本研究期间增殖反应的正变化有显著性。在安慰剂组,平均值从0天的7.3增加到9天的11.8,然后18天降至7.9,在28天再次增加到8.7(图1b)。即使二次项T2具有非显著系数(-0.0008,p=0.141,表3),T的显著估计系数(0.034,p=0.022,表3)显示出轨迹作用。然而,如果ACTIMEL组与安慰剂组比较,统计学检验在两条曲线间未显示任何显著差异(T和T2分别是p=0.630和0.626)。
流感:
ACTIMEL组比安慰剂组显示更清晰的改变。平均值从0天的13±12.6增加到9天的19.7±17.1,保持这个水平到18天,然后在28天降至13.9±12.7(图1c)。估计的T和T2的两个系数与零有显著差异(p=0.001)。这些统计显示本研究期间增殖反应的正改变是显著性的(表2)。
安慰剂组显示与破伤风观察到的那些相似的变化。如图1c图示,平均值到9天增加,到18天降低,到28天再次增加。两个估计的回归系数与0没有显著差异(T和T2的p值分别是0.181和0.475),表明对流感抗原的增殖反应变异没有显著轨迹。
当比较ACTIMEL组和安慰剂组估计的参数时,观察到线性参数和二次方参数都有显著差异(T的p=0.045和T2的p=0.027)(表3)。这些结论表明本研究的两组间增殖反应的变化具有显著差异。
实施例2:干酪乳杆菌对响应流感抗原刺激的T淋巴细胞亚群增殖的作用。
体外对微生物抗原应答的T亚群的确切性质未知。T淋巴细胞特定亚群的任何一个,如表型CD3+CD4+,CD3+CH8+,CD3+CH25+和CD3+CD45+代表的那些,可以认为是初级应答者,或这些组合亚群可能有助于对激发抗原的总体增殖反应。
假设特定淋巴细胞亚群是激发抗原的主要应答者,为了确定ACTIMEL组和安慰剂组之间4个亚群得到的增殖反应是否有显著差异,使用上面实施例1所述的统计模型对T细胞亚群CD3+CD4+,CD3+CH8+,CD3+CH25+和CD3+CD45+进行分析。
在这些分析中,对于每个亚群,最初基于总PBMCs的增殖反应的值转换为根据每个血液样品中CD3+CD4+,CD3+CH8+,CD3+CH25+和CD3+CD45+ T细胞总频率计算的新值。下一步,对每个亚群进行统计学分析,如上面实施例1所述。
对于四个淋巴细胞亚群,每个安慰剂和ACTIMEL组的平均数、标准差和中值在下表4给出。
表4
SD=标准差
淋巴细胞亚群 | 安慰剂 | ACTIMEL | ||||||
0天 | 9天 | 18天 | 28天 | 0天 | 9天 | 18天 | 28天 | |
CD3+CD4+平均数SD中值 | 10184.072.8 | 149130111 | 11311774.5 | 12512791.0 | 87.410463.0 | 13190.2103 | 13311292.0 | 10712764.5 |
CD3+CD8+平均数SD中值 | 192155167 | 268250218 | 251289140.5 | 251336168 | 230375105 | 301286180 | 365554214 | 244302126 |
CD3+CD25+平均数SD中值 | 250219185 | 377374263 | 260208228 | 354462247 | 177139159 | 267163262 | 310210251 | 270305177 |
CD3+CD45+平均数SD中值 | 63.554.147.5 | 87.670.966.6 | 73.081.343.1 | 76.279.751.4 | 52.172.234.0 | 78.756.364.0 | 87.179.267.8 | 69.195.241.0 |
本研究的两组之间基础值的差异无统计学显著性。
使用上面实施例1所述的统计学模型,在对流感抗原应答中,分析四个淋巴细胞亚群中每一个的增殖相对于这些基础值的变异。图2以对数级图示了这些亚群中的每一个和本研究两组中的每个组的增殖的变异。
下表5给出了统计学建模的结果。
表5
SE=标准误
淋巴细胞亚群 | 变量 | 参数估计(SE) | H0检验:参数=0 | 2条曲线的比较 |
CD3+CD45+ | 安慰剂 TT2 | 0.015(0.016)-0.0003(0.0006) | P=0.352P=0.597 | H0:β11=β12P=0.015H0:β21=β22P=0.016 |
ACTIMEL TT2 | 0.071(0.015)-0.0024(0.0006) | P<0.001P<0.001 | ||
CD3+CD25+ | 安慰剂 TT2 | 0.024(0.016)-0.0004(0.0006) | P=0.144P=0.463 | H0:β11=β12P=0.031H0:β21=β22P=0.030 |
ACTIMEL TT2 | 0.071(0.015)-0.0022(0.0006) | P<0.001P<0.001 | ||
CD3+CD8+ | 安慰剂 TT2 | 0.0142(0.017)-0.0003(0.0006) | P=0.410P=0.671 | H0:β11=β12P=0.013H0:β21=β22P=0.012 |
ACTIMEL TT2 | 0.070(0.015)-0.0024(0.0006) | P<0.001P<0.001 | ||
CD3+CD4+ | 安慰剂 TT2 | 0.022(0.017)-0.0005(0.0006) | P=0.203P=0.436 | H0:β11=β12P=0.028H0:β21=β22P=0.024 |
ACTIMEL TT2 | 0.072(0.015)-0.0025(0.0006) | P<0.001P<0.001 |
四个淋巴细胞亚群中每一个的增殖反应与总PBMCs观察到的反应一致。接触流感抗原过程中,观察到ACTIMEL组的四个淋巴细胞亚群有显著变化。这些变化可以以时间的二次函数来表示。
观察到安慰剂组的四个亚群有小的变化。
此外,两组间的所有淋巴细胞亚群具有显著性差异。
结论
这些结果表明,对于检测的3个抗原,抗原激发者诱导的增殖反应增加,该增加在ACTIMEL组高于安慰剂组。在流感抗原的情况下,对于总PBMCs和T细胞亚群CD3+CD4+,CD3+CH8+,CD3+CH25+和CD3+CD45+的每一个来说,ACTIMEL组的增加与安慰剂组观察到的相比,具有统计学显著性。
因此看来在有关的个体中,ACTIMEL摄入诱导体内免疫引发,引起它们的T细胞对微生物抗原尤其是流感抗原的离体反应,这种反应比安慰剂组观察到的好。
该反应的增加与ACTIMEL组个体中CD3+T细胞及其亚群的活化频率和状态有关。
此外,与CD25活化标记的存在正相关提示表达CD25 IL-2受体和能够对流感抗原更有效地应答的流感特异性T细胞体内活化的参与。T细胞亚群的分析也提示增殖反应可能包括与流感抗原对应的CD4+和CD8+亚群。CD3+/CD8+T亚群在分析增殖中的重要性提示流感特异性CD8+细胞毒性细胞库体内引发的可能性。
Claims (7)
1.干酪乳杆菌物种的菌株在制备可口服给药来加强抗病原微生物的特异性全身免疫反应的组合物中的应用。
2.权利要求1的应用,其特征在于所述的病原微生物是呼吸道的病原体。
3.权利要求1和2任一项的应用,其特征在于所述的病原微生物是选自鼻病毒、呼吸道合胞病毒和粘液病毒的病毒。
4.权利要求3的应用,其特征在于所述的病毒是流感病毒。
5.权利要求1至4任一项的应用,其特征在于所述的干酪乳杆菌菌株是CNCM株I-1518。
6.权利要求1至5任一项的应用,其特征在于所述的组合物是食品或食品添加物的形式。
7.权利要求1至6任一项的应用,其特征在于所述的组合物是发酵乳制品的形式。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0006679A FR2809312B1 (fr) | 2000-05-25 | 2000-05-25 | Utilisation de l. casei dans des compositions immunostimulantes |
FR00/06679 | 2000-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1430518A true CN1430518A (zh) | 2003-07-16 |
CN1194707C CN1194707C (zh) | 2005-03-30 |
Family
ID=8850597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018100511A Expired - Fee Related CN1194707C (zh) | 2000-05-25 | 2001-04-27 | 干酪乳杆菌在免疫刺激肽中的应用 |
Country Status (28)
Country | Link |
---|---|
US (1) | US7604809B2 (zh) |
EP (1) | EP1283714B1 (zh) |
JP (1) | JP2003534284A (zh) |
CN (1) | CN1194707C (zh) |
AR (1) | AR028626A1 (zh) |
AT (1) | ATE332143T1 (zh) |
AU (2) | AU5643501A (zh) |
BG (1) | BG65884B1 (zh) |
BR (1) | BR0111135A (zh) |
CA (1) | CA2410350C (zh) |
CZ (1) | CZ303600B6 (zh) |
DE (1) | DE60121327T2 (zh) |
DK (1) | DK1283714T3 (zh) |
EA (1) | EA005081B1 (zh) |
ES (1) | ES2267763T3 (zh) |
FR (1) | FR2809312B1 (zh) |
HK (1) | HK1055898A1 (zh) |
HR (1) | HRP20020935A2 (zh) |
HU (1) | HUP0302041A3 (zh) |
IL (1) | IL152980A0 (zh) |
MA (1) | MA25760A1 (zh) |
MX (1) | MXPA02011636A (zh) |
NO (1) | NO332369B1 (zh) |
PL (1) | PL201801B1 (zh) |
PT (1) | PT1283714E (zh) |
SK (1) | SK18272002A3 (zh) |
WO (1) | WO2001089541A1 (zh) |
ZA (1) | ZA200209087B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102858948A (zh) * | 2010-01-08 | 2013-01-02 | 热尔韦·达诺尼公司 | 具有抗氧化作用的乳酸杆菌 |
CN103097513A (zh) * | 2010-03-12 | 2013-05-08 | 热尔韦·达诺尼公司 | 用于乳糜泻的乳酸菌 |
CN102186486B (zh) * | 2008-10-17 | 2013-07-24 | 皮埃尔法布雷医药公司 | 包括接骨木萃取液和副干酪乳杆菌、干酪乳杆菌、保加利亚乳杆菌或嗜热链球菌的菌株的结合物的组合物 |
CN103220921A (zh) * | 2010-10-15 | 2013-07-24 | 科.汉森有限公司 | 免疫佐剂 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
GB0009294D0 (en) | 2000-04-15 | 2000-05-31 | Sec Dep For The Home Departmen | Improvements in and relating to analysis of DNA samples |
US9610347B2 (en) * | 2001-04-30 | 2017-04-04 | Cortcontrol | Vaccination response for immunodeficiency or high cortisol |
CN1317385C (zh) * | 2003-05-30 | 2007-05-23 | 上海光明乳业股份有限公司 | 干酪乳杆菌Bd-II菌株及其在降低血脂方面的应用 |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
ATE361101T1 (de) * | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
ZA200705844B (en) * | 2004-12-15 | 2008-09-25 | Van Der Westhuzen Corne Floris | Detoxifying and immunity-booster composition |
EP1683425A1 (en) * | 2005-01-21 | 2006-07-26 | Compagnie Gervais Danone | Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction |
ES2264368B1 (es) * | 2005-02-11 | 2007-12-01 | Francisco Exposito Mesa | Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos. |
AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
AU2006253006B8 (en) | 2005-05-31 | 2011-09-15 | Alimentary Health Ltd | Feline probiotic Lactobacilli |
BRPI0716997B8 (pt) | 2006-09-10 | 2021-05-25 | Glycotope Gmbh | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
FR2912657B1 (fr) * | 2007-02-16 | 2009-04-17 | Gervais Danone Sa | Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale. |
WO2009021585A1 (en) * | 2007-08-13 | 2009-02-19 | Dsm Ip Assets B.V. | Probiotic bacteria for rducing the occurence of symptoms of winter infections |
WO2009067000A1 (en) * | 2007-11-20 | 2009-05-28 | N.V. Nutricia | Composition with synbiotics |
EP2119365B1 (de) | 2008-05-13 | 2017-08-16 | Glycotope GmbH | Fermentationsprozess |
US8741365B2 (en) * | 2008-05-13 | 2014-06-03 | Glycotope Gmbh | Fermentation process |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
EP2153837A1 (en) * | 2008-08-14 | 2010-02-17 | Compagnie Gervais Danone | Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
EP2455092A1 (en) * | 2010-11-11 | 2012-05-23 | Nestec S.A. | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
CA2844543A1 (en) | 2011-08-22 | 2013-02-28 | Glycotope Gmbh | Microorganisms carrying a tumor antigen |
WO2014038929A1 (en) | 2012-09-07 | 2014-03-13 | N.V. Nutricia | Probiotics for producing antiviral factors |
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05236872A (ja) * | 1992-02-27 | 1993-09-17 | Takanashi Nyugyo Kk | 乳酸菌含有食品 |
JP4112021B2 (ja) * | 1994-02-16 | 2008-07-02 | 明治乳業株式会社 | 乳酸菌を用いた免疫賦活剤 |
ATE173135T1 (de) * | 1995-01-02 | 1998-11-15 | Gervais Danone Co | Milchsäureferment, und ihre verwendung zur herstellung von antidiarrhöeprodrukten |
ES2349669T3 (es) * | 1997-08-21 | 2011-01-10 | New Zealand Dairy Board | Bacterias del ácido láctico que incrementan la inmunidad. |
US6699517B2 (en) * | 1997-11-28 | 2004-03-02 | Compagnie Gervais Danone | Method for preparing food products by fermenting soy milk with streptococcus thermophilus |
IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
KR100324441B1 (ko) * | 1999-02-08 | 2002-02-27 | 이은선 | 위염, 위궤양, 십이지장궤양 예방을 위한 식품 |
-
2000
- 2000-05-25 FR FR0006679A patent/FR2809312B1/fr not_active Expired - Fee Related
-
2001
- 2001-04-27 CZ CZ20024189A patent/CZ303600B6/cs unknown
- 2001-04-27 HU HU0302041A patent/HUP0302041A3/hu unknown
- 2001-04-27 JP JP2001585785A patent/JP2003534284A/ja active Pending
- 2001-04-27 PT PT01929743T patent/PT1283714E/pt unknown
- 2001-04-27 US US10/276,315 patent/US7604809B2/en not_active Expired - Fee Related
- 2001-04-27 DK DK01929743T patent/DK1283714T3/da active
- 2001-04-27 AU AU5643501A patent/AU5643501A/xx active Pending
- 2001-04-27 MX MXPA02011636A patent/MXPA02011636A/es active IP Right Grant
- 2001-04-27 AU AU2001256435A patent/AU2001256435B2/en not_active Ceased
- 2001-04-27 EP EP01929743A patent/EP1283714B1/fr not_active Expired - Lifetime
- 2001-04-27 CA CA2410350A patent/CA2410350C/fr not_active Expired - Lifetime
- 2001-04-27 EA EA200201248A patent/EA005081B1/ru not_active IP Right Cessation
- 2001-04-27 PL PL358408A patent/PL201801B1/pl unknown
- 2001-04-27 SK SK1827-2002A patent/SK18272002A3/sk not_active Application Discontinuation
- 2001-04-27 DE DE60121327T patent/DE60121327T2/de not_active Expired - Lifetime
- 2001-04-27 IL IL15298001A patent/IL152980A0/xx unknown
- 2001-04-27 AT AT01929743T patent/ATE332143T1/de active
- 2001-04-27 ES ES01929743T patent/ES2267763T3/es not_active Expired - Lifetime
- 2001-04-27 CN CNB018100511A patent/CN1194707C/zh not_active Expired - Fee Related
- 2001-04-27 WO PCT/FR2001/001310 patent/WO2001089541A1/fr active IP Right Grant
- 2001-04-27 BR BR0111135-3A patent/BR0111135A/pt not_active IP Right Cessation
- 2001-05-24 AR ARP010102498A patent/AR028626A1/es unknown
-
2002
- 2002-11-08 ZA ZA200209087A patent/ZA200209087B/xx unknown
- 2002-11-20 BG BG107299A patent/BG65884B1/bg unknown
- 2002-11-21 NO NO20025595A patent/NO332369B1/no not_active IP Right Cessation
- 2002-11-25 HR HR20020935A patent/HRP20020935A2/hr not_active Application Discontinuation
- 2002-12-20 MA MA26968A patent/MA25760A1/fr unknown
-
2003
- 2003-11-12 HK HK03108188A patent/HK1055898A1/xx not_active IP Right Cessation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186486B (zh) * | 2008-10-17 | 2013-07-24 | 皮埃尔法布雷医药公司 | 包括接骨木萃取液和副干酪乳杆菌、干酪乳杆菌、保加利亚乳杆菌或嗜热链球菌的菌株的结合物的组合物 |
CN102858948A (zh) * | 2010-01-08 | 2013-01-02 | 热尔韦·达诺尼公司 | 具有抗氧化作用的乳酸杆菌 |
CN102858948B (zh) * | 2010-01-08 | 2015-11-25 | 热尔韦·达诺尼公司 | 具有抗氧化作用的乳酸杆菌 |
CN103097513A (zh) * | 2010-03-12 | 2013-05-08 | 热尔韦·达诺尼公司 | 用于乳糜泻的乳酸菌 |
CN103097513B (zh) * | 2010-03-12 | 2018-01-30 | 热尔韦·达诺尼公司 | 用于乳糜泻的乳酸菌 |
CN103220921A (zh) * | 2010-10-15 | 2013-07-24 | 科.汉森有限公司 | 免疫佐剂 |
CN103220921B (zh) * | 2010-10-15 | 2015-12-16 | 科.汉森有限公司 | 免疫佐剂 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1194707C (zh) | 干酪乳杆菌在免疫刺激肽中的应用 | |
CN112175864B (zh) | 动物双歧杆菌及其选育方法和应用 | |
CN104480032B (zh) | 一株具有增强免疫活性的植物乳杆菌 | |
CN102835657B (zh) | 用以抑制发炎反应及抗阴道炎的含乳酸菌食品组合物及医药组合物 | |
CN102597216A (zh) | 新型植物乳杆菌及其组合物 | |
CN1219444C (zh) | 制备免疫刺激性乳类产品的方法和其应用 | |
CN110964658B (zh) | 一种具有免疫调节功能的副干酪乳杆菌et-22 | |
JP6337262B2 (ja) | 耐塩性乳酸菌、耐塩性乳酸菌の培養方法、及び免疫賦活剤 | |
CN111944721A (zh) | 一株具有免疫调节作用的鼠李糖乳杆菌及其应用 | |
CN105586299A (zh) | 嗜酸乳杆菌制剂及其应用 | |
CN106795482A (zh) | 允许在营养不良的情况下促进人和动物的幼年生长的乳杆菌组合物 | |
Saman et al. | Evaluation of prebiotic property in edible mushrooms | |
CN114774315A (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
JP2005333919A5 (zh) | ||
CN1777670A (zh) | 具有产生谷氨酰胺的能力的双歧杆菌属的新菌株 | |
KR102369996B1 (ko) | 대사성 질환과 안질환의 예방 및 건강 유지를 위한 장내 미생물 검사 기반 맞춤형 프리바이오틱스 또는 프로바이오틱스 정보 제공방법 | |
CN102210454A (zh) | 一种微生物复合制剂及其制备方法 | |
Bezirtzoglou et al. | Occurrence of Bifidobacterium in the intestine of newborns by fluorescence in situ hybridization | |
CN110982731A (zh) | 一株具有益生特性的太空诱变植物乳杆菌st20-71及其应用 | |
CN1552845A (zh) | 干酪乳杆菌Bd-II菌株及其在降低血脂方面的应用 | |
Umar et al. | Distribution of Bifidobacteria in saliva of infants attending postnatal clinic in three public health facilities in Kaduna Metropolis, Kaduna State, Nigeria | |
WO2023022106A1 (ja) | 整腸剤及び免疫増強剤 | |
CN114717133B (zh) | 一株具有增强骨健康作用的枯草芽孢杆菌及其应用 | |
CN117941649A (zh) | 一种悉生小鼠模型及其构建方法及应用 | |
Weiner et al. | The importance of metagenomics research in human ecological niches and their role in the diagnosis of noninfectious diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GROUPE DANONE GERVAIS CO.,LTD. Free format text: FORMER NAME OR ADDRESS: COMPAGNIE GERVAIS DANOE |
|
CP03 | Change of name, title or address |
Address after: Paris France Patentee after: Gervais Danone SA Address before: French Levallois Perret Patentee before: Gervais Danoni |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050330 Termination date: 20130427 |